A phase II study for Albumin Bound Paclitaxel plus Camrelizumab (SHR1210) as therapy in patients with unresectable locally advanced or metastatic urothelial carcinoma
Latest Information Update: 01 Nov 2022
At a glance
- Drugs Camrelizumab (Primary) ; Paclitaxel (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- 13 Sep 2022 Status changed from not yet recruiting to recruiting.
- 13 Sep 2022 Results (Jan 2022; n=20) presented at the 47th European Society for Medical Oncology Congress.
- 04 Aug 2020 New trial record